Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus by unknown
LETTER TO THE EDITOR Open Access
Dapagliflozin as an adjunct therapy to
insulin in the treatment of patients with
type 1 diabetes mellitus
Hector E. Tamez*, Alejandra L. Tamez, Lucas A. Garza, Mayra I. Hernandez and Ana C. Polanco
Abstract
We have evaluated the efficacy of dapagliflozin in patients with type 1 diabetes mellitus (DM1) without adequate
control. We expected that adding dapagliflozin to this population on top of their base treatment would lower their
HbA1c levels.
We conducted a pragmatic, open, 24-week study of treatment with 10 mg of oral dapagliflozin in patients with DM1
and chronic hyperglycemia. We evaluated glycemic control, lipid profile, weight, and insulin dose. Safety was assessed
by adverse event reporting.
Fasting glucose levels decreased from 176.42 ± 45.33 mg/dL to 139.67 ± 44.42 mg/dL (p = 0.05); although no significant
valued was reached, postprandial glucose showed a decreased tendency from 230.25 ± 52.06 mg/dL to 193.83 ±
45.43 mg/dL (p = 0.08). The hemoglobin A1C (HbA1C) level decreased from 9.18 ± 1.02 (77 ± 11.1 mmol/mol) to 8.05 ±
1.09 % (64 ± 11.9 mmol/mol) (p = 0.0156); total cholesterol decreased from 299 ± 12 to 199 ± 7 mg/dL (p = 0.02);
triglycerides decreased from 184 ± 15 to 160 ± 11 mg/dL (p = 0.0002), HDL-C decreased from 40 ± 17 to 42 ± 9 mg/dL
(p = 0.54); and LDL-C decreased from 187 ± 19 to 170 ± 21 mg/dL (p = 0.049). No adverse events were reported.
The beneficial effects of SGLT2 inhibitors on metabolic control and their safety after a 24-week open study demonstrate
their potential indication as an adjunctive treatment with insulin in patients with DM1; however, long-term clinical trials
should be considered.
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Treatment of Type 1 diabetes mellitus (DM1) is presently
restricted to insulin and in selected cases, pramlintide and
islet or pancreas transplantation [1–3].
In contrast the management of DM1 with oral drugs
is limited. Sodium/glucose cotransporter 2 inhibitors
(SGLT2I), as initial or in combination therapy have
recently been used to treat type 2 diabetes mellitus (DM2)
[4]. These drugs improve glycemic control, promote
weight loss and lower arterial tension; meanwhile, SGLT-2
studies in DM1 are scarce or short-timed [5–8].
The aim of this study was to evaluate the efficacy of dapa-
gliflozin in a group of patients with poorly controlled DM1.
We expected that adding dapagliflozin to this population’s
insulin regimen, would improve their glycemic control.
Research design and methods
We performed an open, 24-week, pragmatic clinical trial
in a group of patients with poorly controlled DM1 in a
private clinic in Monterrey, Nuevo Leon, México from
2013–2014. Twelve patients met the following inclusion
criteria: DM1 according to the American Diabetes Associ-
ation classification [9]; both genders; age greater than
18 years; and elevated glycated hemoglobin A1C (HbA1C)
DDCCT Units (7–10 %) and IFCC Units (53–85.8 mmol/
mol). Patients that presented micro- and macrovascular,
acute hyperglycemia <300 mg/gl (16.64 mmol/L), keto-
nuria, ketoacidosis or hyperosmolarity in the last 6 months
or pregnancy were excluded. Oral dapagliflozin 10 mg was
administered daily to the entire group. Their original insu-
lin regimen (basal/bolus) remained unchanged. Patients
were instructed on detecting hypoglycemia symptoms and
checking their blood glucose.
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Changes in fasting and postprandial glucose (2 h after
the meal) and HbA1C were considered to be the primary
outcomes. Appearance of hypoglycemia, genitourinary or
micotic infections and ketonuria were routinely revised.
The study protocol was approved by the local research
ethics committee.
Results
Twelve patients were included (seven male, five female)
with a mean age of 27 ± 11 years and a mean duration of
disease of 9.17 ± 7.41 years. All were overweight with a
body mass index (BMI) of 27.98 ± 1.97 kg/m2.
The fasting glucose decreased from 176.42 ± 45.33 mg/dL
to 139.67 ± 44.42 mg/dL (p = 0.05). The postprandial glu-
cose decreased from 230.25 ± 52.06 mg/dL to 193.83 ±
45.43 mg/dL; however, it did not reach a significant value
(p = 0.08). HbA1C significally decreased from 9.18 ± 1.02 %
(77 ± 11.1 mmol/mol) to 8.05 ± 1.09 % (64 ± 11.9 mmol/
mol) (p = 0.0156). The lipid profile was modified favorably,
with total cholesterol decreasing from 299 ± 12 to 199 ±
7 mg/dL (p = 0.02), LDL-C from 187 ± 19 to 170 ± 21 mg/
dL (p = 0.049) and triglycerides from 184 ± 15 to 160 ±
11 mg/dL (p = 0.0002). HDL-C was unchanged at 40 ± 17
and 42 ± 9 mg/dL (p = 0.54) (Table 1).
Dapagliflozin was well tolerated. Hypoglycemia, in-
fections, ketonuria or ketoacidosis were not seen.
Discussion
The current report describes a medium-term interven-
tional study in DM1 patients treated daily with 10 mg
dapagliflozin. Treatment with dapagliflozin resulted in an
improvement of both fasting and postprandial glucose
and HbA1C, which may have resulted from a longer treat-
ment period than in previous studies (up to 8 weeks) [8].
The lipid profile also improved following treatment,
with reductions in total cholesterol, c-LDL cholesterol
and triglycerides (all statistically significant). This is in-
consistent with previous SGLT-2 studies and may have
resulted from improved glycemic control, weight loss, or
other causes [4, 9].
An unattained metabolic control of DM1 has prompted
a search for other therapeutic options, like pramlintide or
islets transplantation [1–3, 10–12].
Evidence of efficacy of SGLT2I in DM1 is limited
[13]; however, studies are beginning to appear. Use of
remogliflozin has been stated in small reports, along
with basic studies of SGLT-2I in rats [5, 6, 14]. A case
series in individuals with DM1 reported favorable results in
reducing HbA1C, weight, insulin dose, and hypoglycemic
events; furthermore, it appears SGLT-2I could decrease the
renal hyperfiltration in DM1 patients [5–8]. Another study
that included 40 normotensive patients over a period of
8 weeks reported the pleiotropic actions of SGLT2I and
improvements in cardiovascular risk [8]. A recent re-
port of dapagliflozin study in adults with type 1 dia-
betes demonstrated acceptable short-term tolerability,
and expected pharmacokinetic profiles and increases
in urinary glucose excretion [15].
We believe that dapagliflozin is safe and well tolerated
with no clinically documented adverse effects. In addition,
our study had the strength of a pragmatic design with a
relatively long treatment period.
However, recently the U.S. Food and Drug Administra-
tion (FDA) issued a Drug Safety Communication warning
of an increased risk of diabetic ketoacidosis associated with
the used of all the approved SGLT2I. This potential compli-
cation related is predictable, detectable, and preventable,
with the full picture still favoring the use of SGLT2I DM1
patient [16].
Nevertheless, we recognize that the data should be cau-
tiously considered because the study was performed in a
specialized care center with educated patients and a small
sample size of overweight individuals. Also, we do not have
information regarding the follow up of the patients.
Conclusions
Dapagliflozin as an adjunct therapy to insulin caused
significant changes in the HbA1C level, fasting and
postprandial glucose and atherogenic lipid in patients
with DM1. Thus, dapagliflozin may represent a new
therapeutic approach, although long-term controlled
clinical trials with a greater number of patients are
needed to confirm our data.
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Table 1 Comparison of efficacy
Variables (N = 12) Initial Final P value
Sex (M/male,F/female) M: 7 / F:5
Age (years) 27.67 ± 14
Evolution of DM1 (years) 9.17 ± 7.41
Weight (kg) 78.33 ± 12.06 76.83 ± 11.72 0.76
Insulin U/kg 0.98 ± 0.11 0.96 ± 0.11 0.44
FG (mg/dl)a 176.42 ± 45.33 139.67 ± 44.42 0.05
PPG (mg/dl)b 230.25 ± 52.06 193.83 ± 45.43 0.08
HbA1C (%) 9.18 ± 1.02 8.05 ± 1.09 0.0156
HbA1C (mmol/mol)c 77 ± 11.1 64 ± 11.9 0.0156
Total Cholesterol (mg/dL) 299 ± 12 199 ± 7 0.02
HDL-C (mg/dL) 40 ± 7 42 ± 9 0.54
LDL-C (mg/dl) 187 ± 19 170 ± 21 0.049
Triglycerides (mg/dL) 184 ± 15 160 ± 11 0.0002
Values are means ± SD
aFG: Fasting glucose
bPPG: postprandial glucose
cAccording to the Harmonizing Hemoglobin A1c testing NGSP
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